Clinical Trial Update: Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) [Phase 1]

View source ↗

Summary

Phase 1 single-ascending-dose study of NGP 555 in healthy young volunteers has completed. The trial assessed safety and tolerability for NeuroGenetic Pharmaceut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NGP 555

Snippet

Sponsor: NeuroGenetic Pharmaceuticals Inc | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED